Furthermore, the fact that ~60% of nonresponders to anti-PD-(L)1 therapy belong to a group with high tumor PD-L1 expression19 suggests that there are much broader and more complex immune evasion mechanisms beyond immune checkpoint-mediated suppression in the tumor microenvironment (TME). The gene discussed is CD274; the disease is neoplasm.